Quest Diagnostics (DGX) Fair Value Raised After Q2 Beat
Analysts raised Quest Diagnostics (DGX) fair value from $223.44 to $239.38 following a Q2 earnings beat and higher full-year guidance. Price targets now range from $230 to $265, reflecting varied views on volume and margins.
Key Numbers
Analysts have raised the fair value estimate for Quest Diagnostics (DGX) from $223.44 to $239.38, following the company's better-than-expected Q2 results and increased full-year guidance. The updated fair value comes as price targets shift into the $245-$265 range for more bullish views and into the low $230s for more cautious ones.
Recommendation Change
- Previous Fair Value: $223.44
- New Fair Value: $239.38
- Price Target Range: $230 - $265
Analyst Rationale
The fair value adjustment reflects analysts' assessment of the Q2 earnings beat and higher full-year guidance. The update also incorporates ongoing debates around volume trends and margin performance, which have influenced valuation models.
Context
Quest Diagnostics reported strong Q2 results, prompting analysts to refresh their models. While some analysts are bullish with targets as high as $265, others remain cautious with targets around $230, highlighting uncertainty about sustained growth and margins.
What This Means for Investors
The fair value increase signals analyst confidence in Quest Diagnostics' performance, but the wide range of price targets suggests differing views on future growth and profitability. Investors should weigh these perspectives when making decisions.
Frequently Asked Questions
Found this useful? Share it